Biodexa Pharmaceuticals (BDRX) Operating Leases (2018 - 2025)

Biodexa Pharmaceuticals has disclosed Operating Leases across 8 years of filings, most recently posting $81140.1 for Q4 2025.

• In Q4 2025, Operating Leases fell 64.68% year-over-year to $81140.1; the TTM figure through Dec 2025 stood at $81140.1 (down 64.68% YoY), while the FY2025 annual figure was $80429.1, down 64.85% from the prior year.
• Operating Leases came in at $81140.1 for Q4 2025 at Biodexa Pharmaceuticals, down from $229746.8 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $745449.9 in Q4 2021 to a low of $81140.1 in Q4 2025.
• Average Operating Leases over 5 years is $290986.6, with a median of $209754.7 recorded in 2023.
• Year-over-year, Operating Leases plunged 74.67% in 2022 and gained 11.07% in 2023.
• Over 5 years, Operating Leases stood at $745449.9 in 2021, then sank by 74.67% to $188841.5 in 2022, then climbed by 11.07% to $209754.7 in 2023, then rose by 9.53% to $229746.8 in 2024, then sank by 64.68% to $81140.1 in 2025.
• Per Business Quant data, the three most recent Operating Leases figures were $81140.1 in Q4 2025, $229746.8 in Q4 2024, and $209754.7 in Q4 2023.